Company Veloxis Pharmaceuticals A/S





Delayed Nasdaq Copenhagen 5-day change 1st Jan Change
- DKK -.--% Intraday chart for Veloxis Pharmaceuticals A/S -.--% -0.50%

Business Summary

Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Company’s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Company’s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.


Managers TitleAgeSince
Chief Operating Officer - 16-02-29
Chief Tech/Sci/R&D Officer - 17-09-12
Corporate Officer/Principal - -
Corporate Officer/Principal - -
General Counsel - 16-02-29
Corporate Officer/Principal - 16-03-31
Human Resources Officer - 16-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,739,741,590 173,932,405 ( 9.998 %) 0 9.998 %

Company contact information

Veloxis Pharmaceuticals A/S

Amerika Plads 37

2100, Copenhagen

address Veloxis Pharmaceuticals A/S(VELO)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
  1. Stock Market
  2. Equities
  3. VELO Stock
  4. Company Veloxis Pharmaceuticals A/S